Peptide receptor radionuclide therapy (PRRT) and the pituitary: safety and efficacy

Area of Science:

• Endocrinology
• Nuclear Medicine
• Oncology

Background:

• Aggressive pituitary neuroendocrine tumors (PitNETs) and carcinomas often resist conventional treatments.
• Somatostatin receptors (SSTR), particularly SSTR2, are frequently overexpressed on these tumor cells.
• This overexpression allows for targeted delivery of radiolabeled somatostatin analogs.

Purpose of the Study:

• To review the current evidence on the efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) for aggressive pituitary tumors.
• To assess PRRT's potential as a targeted treatment option for refractory PitNETs.

Main Methods:

• Narrative review of existing literature on PRRT in aggressive pituitary tumors.
• Analysis of reported outcomes regarding tumor response, hormonal control, and symptom relief.
• Evaluation of PRRT-related adverse events and toxicity, including nephroprotection strategies.

Main Results:

• PRRT demonstrated successful outcomes in some cases, including reduced tumor growth and hormonal secretion.
• Symptomatic relief from mass effects was also reported.
• Adverse events were generally mild and transient, primarily hematologic; renal toxicity was uncommon with amino-acid nephroprotection.
• Pituitary function was largely preserved, with no significant PRRT-induced hypopituitarism.

Conclusions:

• PRRT is a biologically rational and potentially effective therapeutic option for selected patients with SSTR-positive aggressive pituitary tumors.
• It offers a targeted approach for patients who have failed previous therapies.